Years Ahead in HIV Prevention Research

Time to Market

daily

Prevention Product	2022 2 Q1 Q2 Q3 Q4 Q1 Q2	2023 2024 2 Q3 Q4 Q1 Q2 Q3 Q4 Q1	2025 Q2 Q3 Q4 Q1	2026 Q2 Q3 Q4 Q2	2027 1 Q2 Q3 Q4	2028 Q1 Q2 Q3 Q4	
Vaginal Ring	Dapivirine monthly Multiple regulatory approvals WHO Guidelines	Multiple implementation science Selected Global Fund procureme		 Unclear den Initial price Oct 2023: A product lice 3-monthly resubmitted to 	ted modest efficacy mand and limited initial su ~\$180/yr memorandum of underst ense with Kiara ing currently in developm o regulators in 2025 to build market and platf	tanding reached on a ent and could be	
Long-Acting Injectables	Cabotegravir One intramuscular injection (3ml) every 2 months Multiple regulatory approvals WHO Guidelines	Multiple implementation so Selected Global Fund and PEP programs		 Unclear der Initial LMIC Mar 2023: I regulatory s 4-monthly f regulatory s 	 Demonstrated high efficacy Unclear demand and limited initial supply Initial LMIC price ~\$240/yr; 2024: ~\$180/yr; 2025: ~\$160/yr Mar 2023: MPP & Viiv licensed to 3 generics with likely regulatory submission by 2027 4-monthly formulation currently in development, with regulatory submission expected early 2026 Opportunity to build market and platforms for injectables 		
	Lenacapavir Two subcutaneous injections (1.5 ml each) every 6 months Phase 3: PURPOSE 1 &	Initial results showed no infections in the LEN arm for PURPOSE 1 and a 96% reduction in HIV infections compared to background HIV incidence for PURPOSE 2 Phase 2: PURPOSE 3, 4, 5	by US Possible product intro	 Dec 2024: million use Initial LMIC Oct 2024: 	ated very high efficacy Global Fund & PEPFAR co ers in first 3 yrs C price unclear Gilead licensed to 6 general		
Oral PrEP	F/TAF daily Phase 3: p	Phase 3: part of PURPOSE 1		 Once-yearl regulatory 	 regulatory submission by 2027 Once-yearly formulation currently in development, with regulatory submission expected in 2027 Opportunity to understand if market can bear 2 injectables 		
	MK-8527 monthly	Phase 2a: MK-8527-07		unch in Q3 2025			
Dual Prevention Pill	Co-formulated TDF/FTC and ethinyl estradiol/ levonorgestrel oral contraceptive	e (BE) Pivotal BE	Possible regulate approva	introductio	n		

Acceptability Study: HPTN 104